Editorial comparison

Retatrutide vs tirzepatide

Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)

Last updated 2026-07-19

These two are not comparable products at different price points. Tirzepatide is a licensed prescription-only medicine in the UK. Retatrutide is investigational, holds no marketing authorisation anywhere, and cannot lawfully be supplied for human use here. Pharmacologically retatrutide is described as a triple agonist and tirzepatide as a dual agonist, but that is the less consequential difference. On 28 May 2026 the MHRA made its largest ever seizure of unlicensed weight-loss medicines, recovering around 12,000 doses that included retatrutide, tirzepatide and other peptide products, and arrested two men. That is the context anyone searching this comparison should have.

AI-friendly summary · Retatrutide vs tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed in the UK as a prescription-only medicine. Retatrutide is a triple agonist at the GLP-1, GIP and glucagon receptors, is still in clinical development, and holds no marketing authorisation anywhere. Retatrutide is sold in the UK by research-peptide sellers under research-use-only labelling, which is a labelling convention and not a legal exemption. The MHRA named retatrutide in its largest ever seizure of unlicensed weight-loss medicines in May 2026. PeptideClear publishes no dosing or human-use guidance for either.

Side by side

	Retatrutide	Tirzepatide
Drug class	Triple agonist, acting at the GLP-1, GIP and glucagon receptors	Dual agonist, acting at the GIP and GLP-1 receptors
UK licensing status	Not licensed. Investigational, still in clinical development.	Licensed for weight management and for type 2 diabetes.
Legal category in the UK	No marketing authorisation. Supply for human use is unlawful.	Prescription-only medicine.
How it is sold in the UK	Widely listed by research-peptide sellers under "research use only" labelling. That label does not make supply for human use lawful.	Dispensed by registered pharmacies and clinics against a prescription.
Regulator attention	Named by the MHRA in its largest ever seizure of unlicensed weight-loss medicines, 28 May 2026, alongside tirzepatide and other peptide products. Two arrests were made.	Subject of an MHRA falsified-product alert in February 2026 concerning fake branded pens dispensed by a registered UK pharmacy.
Published human evidence	Phase 2 results are published and a phase 3 programme is under way. It has not completed the regulatory process anywhere.	Completed phase 3 programmes supported its UK and international marketing authorisations.
Quality assurance if bought online	None. There is no marketing authorisation, no batch release by a regulator, and no pharmacy accountability. Purity and sterility are unverified.	A licensed product dispensed by a GPhC-registered pharmacy is batch-controlled. A product bought outside that route is not.

Regulatory facts checked against gov.uk on 19 Jul 2026. See the MHRA enforcement and safety tracker and the retatrutide UK regulatory status page.

The comparison people actually want, and why we will not make it

The search behind this page is usually not academic. It is someone weighing a licensed medicine they would need a prescription for against an unlicensed one they could order tonight. We are not going to help with that weighing by putting efficacy numbers side by side, because the numbers for an investigational compound come from trials run under conditions that have nothing in common with a vial bought online, and quoting them next to a purchase decision is exactly the promotion the rules exist to prevent.

What we can usefully tell you is what the regulator has published, what the legal position is, and how to tell a legitimate supply route from an illegal one. That is below.

Before you buy anywhere

How to check a weight-loss medicine seller is legitimate

Six checks separate a legitimate UK supply route from an illegal one: the seller is on the GPhC register, the prescriber is on the GMC register, a real prescription is issued, the product is a UK-licensed medicine, the price sits in the registered-pharmacy range, and the site is not selling a prescription medicine under a "research use only" label. The scale is not theoretical. The MHRA reported seizing almost 20 million doses of illegally traded medicines in 2025, including more than 5,000 illegally traded GLP-1 products, and in 2026 the High Court began ordering UK internet providers to block counterfeit semaglutide websites outright.

A UK seller must be on a register

A legitimate UK online pharmacy appears on the General Pharmaceutical Council register, and the doctor prescribing for you appears on the GMC register. Both registers are free, public and searchable. A seller who is on neither is not a UK pharmacy, whatever the website says.

Search the GPhC register

No prescription means no legitimate supply

Every GLP-1 weight-management medicine licensed in the UK is prescription-only. If a site will sell you one without a consultation and a prescriber, that supply is illegal under the Human Medicines Regulations 2012. There is no exception for a questionnaire that nobody reads.

Human Medicines Regulations 2012

"Research use only" is not a loophole

Selling a medicine under a research-only label does not take it outside medicines law. Where a product is presented as having medicinal effects, the MHRA treats it as a medicine regardless of how it is labelled. In May 2026 the MHRA made its largest ever seizure of unlicensed weight-loss medicines, recovering around 12,000 doses that included retatrutide, tirzepatide and peptide products.

MHRA, 29 May 2026

Counterfeits reach real pharmacies too

In February 2026 the MHRA contacted patients who may have been dispensed fake Mounjaro KwikPen 15mg pens, batch D873576, by a registered Birmingham pharmacy. Testing found the pens did contain tirzepatide, but the manufacturing conditions were unknown so sterility could not be confirmed. Register membership lowers your risk. It does not remove it.

MHRA alert, 24 Feb 2026

Price far below the market is a red flag

Licensed GLP-1 medicines have a real manufacturing and distribution cost. A price well under what registered UK pharmacies charge is not a bargain that others have missed, it is a signal about what is in the box. Compare against the range on our clinic and pharmacy pages before you buy anywhere.

What UK routes actually cost

Report it, and report side effects

If you think a site is supplying medicines illegally, or a product you received is counterfeit, the MHRA has a reporting route. If you have had a side effect from any medicine, report it through the Yellow Card scheme. Patients can report directly, and those reports feed the UK safety monitoring system.

Yellow Card scheme

Sources: MHRA enforcement and safety announcements on gov.uk, the General Pharmaceutical Council register, and the Human Medicines Regulations 2012. Checked 19 Jul 2026 and tracked on our MHRA enforcement tracker. PeptideClear is editorial and does not prescribe, dispense or sell medicines.

Frequently asked questions

Is retatrutide legal to buy in the UK?

Retatrutide holds no marketing authorisation in the UK, so there is no lawful route to obtain it for human use. Sellers list it under "research use only" labelling, but under the Human Medicines Regulations 2012 a product presented as having medicinal effects is treated as a medicine regardless of how it is labelled. In May 2026 the MHRA carried out its largest ever seizure of unlicensed weight-loss medicines and named retatrutide among the products recovered.

How is retatrutide different from tirzepatide?

Retatrutide is described as a triple agonist, acting at the GLP-1, GIP and glucagon receptors. Tirzepatide is a dual agonist, acting at GIP and GLP-1. The more important difference for a UK reader is regulatory rather than pharmacological: tirzepatide has completed the licensing process and retatrutide has not.

Does "research use only" make it legal?

No. It is a labelling convention, not a legal exemption. It can support a lawful supply chain for genuine laboratory research where no medicinal claim is made. It does not authorise supply for human use, and it does not protect a seller who markets a product for weight loss.

What is actually in a grey-market retatrutide vial?

Nobody can tell you without testing that specific batch. There is no regulator releasing batches, no pharmacy accountable for what is dispensed, and no requirement on the seller to publish anything. The only observable signal available before purchase is whether the seller publishes a batch-specific certificate of analysis from a named third-party laboratory, which is what our CoA Trust Index scores. A certificate is a transparency signal about the seller. It is not a safety guarantee and it is not a substitute for a licence.

Why does PeptideClear cover retatrutide at all?

Because people search for it and are buying it, and the honest response to that is accurate information about its status rather than silence. We publish what it is, what its legal position is, and what the regulator has done. We publish no dosing, no protocols and no human-use guidance for it.

Check it yourself: the official sources

PeptideClear is editorial. Nothing here replaces the regulator, and you should not take our word for any of it. These are the official UK destinations where the underlying position is published, free to read and open to anyone.

legislation.gov.uk
Human Medicines Regulations 2012
The legislation that defines what counts as a medicine in the UK, and what constitutes illegal supply. A product marketed with medicinal claims is regulated as a medicine regardless of how it is labelled.
World Anti-Doping Agency
WADA Prohibited List
The annually updated list of substances and methods banned in sport. Many research peptides sit under S0 or S2. UK Anti-Doping enforces it on tested athletes.
MHRA
Report a fake or illegally supplied medicine
The MHRA route for reporting a website or seller supplying medicines illegally, and for reporting a product you believe is counterfeit.
MHRA
Yellow Card scheme
Report a suspected side effect, a defective medicine, or a fake or counterfeit product. Anyone can report, including patients. Reports feed the MHRA safety monitoring system.
MHRA
MHRA Products portal
The Summary of Product Characteristics and Patient Information Leaflet for every medicine licensed in the UK. This is the authoritative document for what a medicine is licensed to do.